{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039997","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.911315+00:00","generated_at":"2026-06-08T06:23:44.580755+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Daré Bioscience reports Q3 2023 cash of $13.8M; XACIATO milestone triggered","bullets":["Cash and equivalents $13.8M at September 30, 2023; evaluating financing options.","R&D expenses increased to $6.7M in Q3 2023 from $4.5M in Q3 2022, driven by Sildenafil Cream and Ovaprene activities.","G&A expenses unchanged at $2.7M; focus on efficient operations.","Received $1.8M first commercial milestone payment from Organon for XACIATO US launch.","On track to start Ovaprene Phase 3 enrollment in Q4 2023 and end-of-Phase 2 meeting for Sildenafil Cream with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039997","json":"https://secwatch.observer/filing/0001493152-23-039997.json","markdown":"https://secwatch.observer/filing/0001493152-23-039997.md","text":"https://secwatch.observer/filing/0001493152-23-039997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/0001493152-23-039997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:23:44.580755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e18627ee7f866baebf6dd0799fde47d26e4337ff","claim":"Dare Bioscience, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/0001493152-23-039997-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}